Daiichi Sankyo Co Ltd 2022 IR
The report highlights Daiichi Sankyo Group's progress during the first year of its five-year business plan (FY2021–FY2025), focusing on its transition to a global oncology leader. Key achievements include the successful expansion of Enhertu sales to 25 countries and regions, as well as positive clinical trial results for breast cancer treatments. The company also advanced its environmental goals by joining the RE100 initiative and revising its Scope 1 and Scope 2 emissions reduction targets to align with the 1.5°C pathway. Additionally, Daiichi Sankyo established wholly owned subsidiaries in Australia, Canada, and Singapore to strengthen its global business foundation.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2022
Type: IR
Pages: 112
Back to company
Daiichi Sankyo Co Ltd
Value Report
The report highlights Daiichi Sankyo Group's progress during the first year of its five-year business plan (FY2021–FY2025), focusing on its transition to a global oncology leader. Key achievements include the successful expansion of Enhertu sales to 25 countries and regions, as well as positive clinical trial results for breast cancer treatments. The company also advanced its environmental goals by joining the RE100 initiative and revising its Scope 1 and Scope 2 emissions reduction targets to align with the 1.5°C pathway. Additionally, Daiichi Sankyo established wholly owned subsidiaries in Australia, Canada, and Singapore to strengthen its global business foundation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Net Zero Target
Employees